Toronto Dominion Bank cut its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 12.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 174,462 shares of the pharmaceutical company’s stock after selling 23,925 shares during the period. Toronto Dominion Bank owned 0.07% of Vertex Pharmaceuticals worth $50,652,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Healthcare of Ontario Pension Plan Trust Fund bought a new position in Vertex Pharmaceuticals in the first quarter valued at approximately $28,000. Manchester Financial Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $30,000. Anderson Fisher LLC grew its stake in shares of Vertex Pharmaceuticals by 530.0% during the second quarter. Anderson Fisher LLC now owns 126 shares of the pharmaceutical company’s stock worth $37,000 after purchasing an additional 106 shares during the period. Duncker Streett & Co. Inc. bought a new stake in Vertex Pharmaceuticals in the second quarter valued at about $44,000. Finally, Baystate Wealth Management LLC lifted its stake in Vertex Pharmaceuticals by 37.3% in the second quarter. Baystate Wealth Management LLC now owns 151 shares of the pharmaceutical company’s stock valued at $44,000 after buying an additional 41 shares during the period. 92.17% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals stock traded up $0.80 during mid-day trading on Wednesday, hitting $267.65. 43,174 shares of the company’s stock traded hands, compared to its average volume of 1,761,720. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.72 and a quick ratio of 3.60. The firm has a 50 day simple moving average of $270.57 and a two-hundred day simple moving average of $264.88. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $165.23 and a fifty-two week high of $306.08. The stock has a market cap of $68.97 billion, a price-to-earnings ratio of 33.97, a P/E/G ratio of 1.54 and a beta of 0.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, July 30th. The pharmaceutical company reported $2.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.75 by $0.86. Vertex Pharmaceuticals had a net margin of 38.51% and a return on equity of 28.55%. The company had revenue of $1.52 billion during the quarter, compared to analysts’ expectations of $1.41 billion. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 8.46 earnings per share for the current fiscal year.

A number of analysts have recently commented on the company. SVB Leerink upped their price target on Vertex Pharmaceuticals from $274.00 to $283.00 and gave the company a “market perform” rating in a research note on Monday, August 24th. Cantor Fitzgerald increased their target price on shares of Vertex Pharmaceuticals from $293.00 to $305.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Credit Suisse Group boosted their price target on shares of Vertex Pharmaceuticals from $298.00 to $328.00 and gave the company an “outperform” rating in a report on Monday, July 20th. HC Wainwright reaffirmed a “buy” rating and set a $315.00 price objective (up previously from $295.00) on shares of Vertex Pharmaceuticals in a research note on Friday, July 31st. Finally, Cowen lifted their target price on Vertex Pharmaceuticals from $265.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $296.15.

In other Vertex Pharmaceuticals news, CFO Charles F. Wagner, Jr. sold 700 shares of the company’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $293.15, for a total value of $205,205.00. Following the transaction, the chief financial officer now directly owns 16,786 shares of the company’s stock, valued at approximately $4,920,815.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Jeffrey M. Leiden sold 32,792 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $286.15, for a total value of $9,383,430.80. Following the transaction, the chairman now owns 29,252 shares in the company, valued at approximately $8,370,459.80. The disclosure for this sale can be found here. Insiders have sold 41,204 shares of company stock valued at $11,836,329 over the last 90 days. Company insiders own 0.48% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.

Read More: How to find the components of the quick ratio

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.